[Federal Register: January 10, 2006 (Volume 71, Number 6)]
[Notices]
[Page 1544-1545]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr10ja06-39]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, Public Health Service, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of federally-funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
for companies and may also be available for licensing.
ADDRESSES: Licensing information and copies of the U.S. patent
applications listed below may be obtained by writing to the indicated
licensing contact at the Office of Technology Transfer, National
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville,
Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A
signed Confidential Disclosure Agreement will be required to receive
copies of the patent applications.
Polysaccharide Derived Nitric Oxide Releasing Carbon Bound
Diazeniumdiolates
Joseph A. Hrabie et al. (NCI)
U.S. Provisional Application No. 60/731,946 filed 31 Oct 2005 (HHS
Reference No. E-279-20050-US-01)
Licensing Contact: John Stansberry; 301/435-5236; stansbej@mail.nih.gov
The invention discloses a method for producing nitric oxide(NO)-
releasing derivatives of any material containing a reducing sugar
component. It may be used to produce NO-releasing cotton bandages or
surgical fabrics, cellulose filters or dialysis membranes, and drug
formulating/compounding agents to prevent stomach irritation. The
method involves incorporation of a diazeniumdiolate (-
N2O2) group at one or more carbons via the base-
catalyzed replacement of acidic hydrogens and is thus compatible with
traditional polysaccharide processing techniques. Monosaccharides such
as glucose may also be derivatized.
In addition to licensing, the technology is available for further
development through collaborative research opportunities with the
inventors.
Hydropneumatic Fluid Control for a Cell Culturing System
Alexandr Chanturiya, Svetlana Glushakova, and Joshua Zimmerberg (NICHD)
U.S. Provisional Application No. 60/725,327 filed 12 Oct 2005 (HHS
Reference No. E-166-2005/0-US-01)
Licensing Contact: Michael Shmilovich; 301/435-5019;
shmilovm@mail.nih.gov
Available for licensing and commercial development is a
hydropneumatic fluid control system in which cell culture media is
perfused through a bioreactor by gas pressure where the direction of
the gas directs the direction of perfusion. The gas can also act to
regulate the pH of the cell culture media. Containers holding the cell
culture media are situated on either side of an axis of rotation of a
platform. The weight of the container as it fills with media forces the
platform to oscillate. The oscillation actuates a piston--also coupled
to the platform--which regulates a valve that switches the flow of gas
to the other container. This system does not use electricity and, with
an appropriate gas mixture, saturates cell culture media with gas.
In addition to licensing, the technology is available for further
[[Page 1545]]
development through collaborative research opportunities with the
inventors.
A Knockout Mouse for Transcription Factor Nurr1
Dr. Vera Nikodem (NIDDK)
HHS Reference No. E-024-1999/0--Research Tool
Licensing Contact: Marlene Shinn-Astor; 301/435-4426;
shinnm@mail.nih.gov
Transcriptional factor Nurr1 is an obligatory factor for
neurotransmitter dopamine biosynthesis only in ventral midbrain as
demonstrated by the Nurr1 genomic locus inactivation using homologous
recombination.
From a neurological and clinical perspective, it suggests an
entirely new mechanism for dopamine depletion in a region where
dopamine is known to be involved in Parkinson's disease. Clinically,
our findings indicate that activation of Nurr1 may be therapeutically
useful for Parkinson's disease patients; therefore, the mice would be
useful in Parkinson's disease research.
Dated: January 3, 2006.
Steven M. Ferguson,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. E6-86 Filed 1-9-06; 8:45 am]
BILLING CODE 4140-01-P